| Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells DC Bishop, LE Clancy, R Simms, J Burgess, G Mathew, L Moezzi, ... Blood, The Journal of the American Society of Hematology 138 (16), 1504-1509, 2021 | 136 | 2021 |
| Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience BE Kiely, G McCaughan, S Christodoulou, PJ Beale, P Grimison, ... Supportive Care in Cancer 21, 369-376, 2013 | 68 | 2013 |
| Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update EJ Favaloro, G McCaughan, L Pasalic Pathology 49 (4), 346-355, 2017 | 51 | 2017 |
| Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID19 pandemic P Di Ciaccio, G McCaughan, J Trotman, PJ Ho, CY Cheah, ... Internal Medicine Journal 50 (6), 667-679, 2020 | 48 | 2020 |
| HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia EJ Favaloro, G McCaughan, S Mohammed, KKE Lau, R Gemmell, ... Pathology 50 (4), 426-436, 2018 | 47 | 2018 |
| Anticoagulation at the extremes of body weight: choices and dosing GJB McCaughan, EJ Favaloro, L Pasalic, J Curnow Expert review of hematology 11 (10), 817-828, 2018 | 35 | 2018 |
| Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma GJB McCaughan, MJ Fulham, A Mahar, J Soper, AM Hong, PD Stalley, ... Journal of Hematology & Oncology 9, 1-5, 2016 | 35 | 2016 |
| Third-party CMV-and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant W Jiang, LE Clancy, S Avdic, G Sutrave, J Street, R Simms, HM McGuire, ... Blood Advances 6 (17), 4949-4966, 2022 | 31 | 2022 |
| Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis G McCaughan, J Massey, I Sutton, J Curnow Case Reports 2017, bcr-2017-223016, 2017 | 22 | 2017 |
| Anticoagulation therapy in Australia EJ Favaloro, GJB McCaughan, S Mohammed, L Pasalic Annals of Blood 3, 2018 | 17 | 2018 |
| COVID19 vaccination in haematology patients: an Australian and New Zealand consensus position statement G McCaughan, P Di Ciaccio, M AnandaRajah, N Gilroy, R MacIntyre, ... Internal medicine journal 51 (5), 763-768, 2021 | 15 | 2021 |
| Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review GJ McCaughan, S Gandolfi, JJ Moore, PG Richardson British Journal of Haematology 199 (2), 190-204, 2022 | 13 | 2022 |
| Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis FW Hoff, R Banerjee, AM Khan, G McCaughan, B Wang, X Wang, ... Blood cancer journal 14 (1), 52, 2024 | 6 | 2024 |
| Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians R Banerjee, B Wang, LD Anderson Jr, G McCaughan, N Mehra, ... Blood cancer journal 13 (1), 162, 2023 | 4 | 2023 |
| P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY. M Lasica, A Spencer, P Campbell, C Wallington-Gates, NW Doo, ... HemaSphere 6, 836-837, 2022 | 4 | 2022 |
| An unexpected diagnosis: leukaemic presentation of blastic plasmacytoid dendritic cell neoplasm with massive splenomegaly R Blennerhassett, G McCaughan, E Tegg Pathology 50 (7), 773-775, 2018 | 4 | 2018 |
| Organ donation in Australia G McCaughan Internal medicine journal 40 (8), 603-604, 2010 | 4 | 2010 |
| Retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma FW Hoff, R Banerjee, A Khan, G McCaughan, XW Wang, J Roose, ... Blood 142, 544, 2023 | 3 | 2023 |
| Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometrybased proteomics in an Australian cohort B Withers, G McCaughan, C Hayward, E Kotlyar, A Jabbour, S Rainer, ... Internal medicine journal 52 (1), 69-78, 2022 | 3 | 2022 |
| A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed … H Quach, M Lasica, D Routledge, A Kalff, A Lim, M Low, JA Estell, ... Journal of Clinical Oncology 39 (15_suppl), TPS8055-TPS8055, 2021 | 3 | 2021 |
